A Phase 3 Study to Demonstrate the Safety and Efficacy of Recombinant Platelet Activating Factor Acetylhydrolase (Pafase) for Reducing 29 Day Mortality in Patients with Severe Sepsis

  • Kearney, Paul (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date9/1/019/1/03